TY - JOUR
T1 - Transplant Outcomes in Bone Marrow Failure Syndromes and Hemoglobinopathies
AU - MacMillan, Margaret L.
AU - Walters, Mark C.
AU - Gluckman, Eliane
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure remains a significant problem, UCB transplantation (UCBT) using the optimal conditioning regimen can be a salvage treatment for patients without a suitable BM donor and warrants evaluation in further prospective studies.
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure remains a significant problem, UCB transplantation (UCBT) using the optimal conditioning regimen can be a salvage treatment for patients without a suitable BM donor and warrants evaluation in further prospective studies.
UR - http://www.scopus.com/inward/record.url?scp=72649101967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72649101967&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2009.10.004
DO - 10.1053/j.seminhematol.2009.10.004
M3 - Article
C2 - 20109610
AN - SCOPUS:72649101967
SN - 0037-1963
VL - 47
SP - 37
EP - 45
JO - Seminars in hematology
JF - Seminars in hematology
IS - 1
ER -